In vivo impact of killer DC-DC hybrids on allo-DTH responses.

(A,B) BALB/c mice (10 mice/panel/experiment) were immunized by SC injection of spleen cells derived from A/J (A) or C57BL/6 mice (B) on day 0 and challenged with the same antigens in the right hind footpad on day 7. These animals received IV injections of PBS alone, killer DC-DC hybrids (clone 8), or control DC-DC hybrids on days −6, −4, 0, 3, and 6. Data are representative of 2 independent experiments, showing the individual data points and the means ± SD of footpad swelling on day 8. (*P < .01; brackets indicate groups being compared.) (C,D) BALB/c mice (C) or A/J mice (D) (5 mice/panel/experiment) were initially immunized on day 0 by SC injection of spleen cells isolated from the indicated allogeneic strain or PBS alone. All animals were subsequently challenged with allogeneic spleen cells on days 7, 14, and 60. These animals were treated with IV injections of PBS alone or killer DC-DC hybrids (clone 8) on days −6, −4, 0, 3, and 6. Data are representative of 2 independent experiments, showing the individual data points and the means ± SD of footpad swelling at 24 hours after each challenge. (*P < .01; brackets indicate groups being compared.)